Growth Hormone differentially modulates chemoresistance in human endometrial adenocarcinoma cell lines

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Endocrine

• Publication date

  2017-06-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1007/s12020-016-1085-4PMID 27585662
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Endometrial cancer.

  2016cited by this paper
• Protein Kinase C Delta restrains growth in ACTH-secreting pituitary adenoma cells.

  2016cited by this paper
• Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012

  2015cited by this paper
• Tetrathiomolybdate mediates cisplatin-induced p38 signaling and EGFR degradation and enhances response to cisplatin therapy in gynecologic cancers

  2015cited by this paper
• Cisplatin in cancer therapy: molecular mechanisms of action.

  2014cited by this paper
• Growth Hormone and Reproduction: A Review of Endocrine and Autocrine/Paracrine Interactions

  2014cited by this paper
• Mitotane enhances doxorubicin cytotoxic activity by inhibiting P-gp in human adrenocortical carcinoma cells

  2014cited by this paper
• How Taxol/paclitaxel kills cancer cells

  2014cited by this paper
• Antitumor Effects and Biological Mechanism of Action of the Aqueous Extract of the Camptotheca acuminata Fruit in Human Endometrial Carcinoma Cells

  2014cited by this paper
• Biologic Effects of Platelet-Derived Growth Factor Receptor α Blockade in Uterine Cancer

  2014cited by this paper
• DNA Damaging Drugs

  2014cited by this paper
• Inhibitory effects of mitotane on viability and secretory activity in mouse gonadotroph cell lines.

  2014cited by this paper
• miR-26 a Plays an Important Role in Cell Cycle Regulation in ACTH-Secreting Pituitary Adenomas by Modulating Protein Kinase C

  2013cited by this paper
• Overall survival and disease-free survival in endometrial cancer: prognostic factors in 276 patients

  2013cited by this paper
• Utilization of genomic signatures to identify high‐efficacy candidate drugs for chemorefractory endometrial cancers

  2013cited by this paper
• miR-26a Plays an Important Role in Cell Cycle Regulation in ACTH-Secreting Pituitary Adenomas by Modulating Protein Kinase Cδ

  2013cited by this paper
• The β6-integrin-ERK/MAP kinase pathway contributes to chemo resistance in colon cancer.

  2013cited by this paper
• Cisplatin increases B‐cell‐lymphoma‐2 expression via activation of protein kinase C and Akt2 in endometrial cancer cells

  2012cited by this paper
• The BCL2 antagonist of cell death pathway influences endometrial cancer cell sensitivity to cisplatin.

  2012cited by this paper
• Growth hormone receptor blockade inhibits growth hormone-induced chemoresistance by restoring cytotoxic-induced apoptosis in breast cancer cells independently of estrogen receptor expression.

  2012cited by this paper
• The resistance of intracellular mediators to doxorubicin and cisplatin are distinct in 3D and 2D endometrial cancer

  2012cited by this paper
• ERK1/2 MAP kinases: structure, function, and regulation.

  2012cited by this paper
• Fibroblast Growth Factor Receptor Inhibition Synergizes With Paclitaxel and Doxorubicin in Endometrial Cancer Cells

  2012cited by this paper
• Down-regulation of IGF-1R expression inhibits growth and enhances chemosensitivity of endometrial carcinoma in vitro

  2011cited by this paper
• Doxorubicin pathways: pharmacodynamics and adverse effects

  2011cited by this paper
• Targeting protein kinase C by Enzastaurin restrains proliferation and secretion in human pancreatic endocrine tumors.

  2011cited by this paper
• Growth hormone affects gene expression and proliferation in human prostate cancer cells.

  2011cited by this paper
• The GH/IGF-1 system in critical illness.

  2011cited by this paper
• Cancer Statistics, 2009

  2010cited by this paper
• The prevalence of benign and malignant neoplasms in acromegalic patients.

  2010cited by this paper
• Magmas, a gene newly identified as overexpressed in human and mouse ACTH-secreting pituitary adenomas, protects pituitary cells from apoptotic stimuli.

  2010cited by this paper
• Endometrial Carcinoma: A Review of Chemotherapy, Drug Resistance, and the Search for New Agents

  2010cited by this paper
• Growth hormone excess promotes breast cancer chemoresistance.

  2009cited by this paper
• Resistance to chemotherapy and hormone therapy in endometrial cancer.

  2009cited by this paper
• ERK signaling pathway may induce gemcitabine chemoresistance in pancreatic cancer cell line SW1990 by regulating the expression of mdr-1 and RRM1 gene

  2009cited by this paper
• Cancer Statistics, 2009

  2009cited by this paper
• The Contribution of Growth Hormone to Mammary Neoplasia

  2008cited by this paper
• Autocrine human growth hormone stimulates oncogenicity of endometrial carcinoma cells.

  2008cited by this paper
• Development of multimarker panel for early detection of endometrial cancer. High diagnostic power of prolactin.

  2007cited by this paper
• Role of anthracyclines in the era of targeted therapy

  2007cited by this paper
• Systemic chemotherapy for uterine carcinoma: metastatic and adjuvant.

  2007cited by this paper
• Pharmacogenetics of paclitaxel metabolism.

  2007cited by this paper
• Human growth hormone and interleukin-6 are upregulated in endometriosis and endometrioid adenocarcinoma.

  2006cited by this paper
• Activation of Akt and ERK signalling pathways induced by etoposide confer chemoresistance in gastric cancer cells.

  2006cited by this paper
• Enhancement of Cisplatin Sensitivity of Cisplatin-Resistant Human Cervical Carcinoma Cells by Bryostatin 1

  2005cited by this paper
• Cisplatin resistance is associated with deregulation in protein kinase C-delta.

  2004cited by this paper
• Growth hormone inhibits apoptosis in human colonic cancer cell lines: antagonistic effects of peroxisome proliferator activated receptor-gamma ligands.

  2004cited by this paper
• Immunohistochemical Localization of the Growth Hormone in Human Endometrium and Decidua

  2004cited by this paper
• AKT involvement in cisplatin chemoresistance of human uterine cancer cells.

  2004cited by this paper
• GH prevents apoptosis in cardiomyocytes cultured in vitro through a calcineurin-dependent mechanism.

  2004cited by this paper
• Population pharmacokinetic modelling of unbound and total plasma concentrations of paclitaxel in cancer patients.

  2003cited by this paper
• Cisplatin: mode of cytotoxic action and molecular basis of resistance

  2003cited by this paper
• 2-aroylindoles, a novel class of potent, orally active small molecule tubulin inhibitors.

  2002cited by this paper
• Protein kinase C delta (PKC delta): activation mechanisms and functions.

  2002cited by this paper
• Kinetics of cisplatin binding to cellular DNA and modulations by thiol-blocking agents and thiol drugs.

  2002cited by this paper
• Protein Kinase Cδ (PKCδ): Activation Mechanisms and Functions

  2002cited by this paper
• Involvement of protein kinase C-δ in DNA damage-induced apoptosis

  2001cited by this paper
• Involvement of protein kinase C-delta in DNA damage-induced apoptosis.

  2001cited by this paper
• Growth Hormone Stimulates Phosphorylation and Activation of Elk-1 and Expression of c-fos, egr-1, andjunB through Activation of Extracellular Signal-regulated Kinases 1 and 2*

  1998cited by this paper
• Minimal antiproliferative effect of recombinant müllerian inhibiting substance on gynecological tumor cell lines and tumor explants.

  1989cited by this paper
• Paradoxical hypersecretion of growth hormone in patients with endometrial atypical hyperplasia and carcinoma. Effect of hysterectomy.

  1982cited by this paper

• Combination of growth hormone receptor antagonist and radiation reduces tumour growth in a lung cancer xenograft model.

  2025cites this paper
• Growth Hormone Action as a Target in Cancer: Significance, Mechanisms and Possible Therapies.

  2024cites this paper
• Growth hormone reduces aneuploidy and improves oocytes quality by JAK2-MAPK3/1 pathway in aged mice

  2023cites this paper
• YTHDF1 Protects Auditory Hair Cells from Cisplatin-Induced Damage by Activating Autophagy via the Promotion of ATG14 Translation

  2022cites this paper
• Growth hormone receptor antagonism downregulates ATP-binding cassette transporters contributing to improved drug efficacy against melanoma and hepatocarcinoma in vivo

  2022cites this paper
• Covert actions of growth hormone: fibrosis, cardiovascular diseases and cancer

  2022cites this paper
• Growth Hormone and Aging: New Findings

  2021cites this paper
• Signaling and Drug Resistance

  2021cites this paper
• Dual Characters of GH-IGF1 Signaling Pathways in Radiotherapy and Post-radiotherapy Repair of Cancers

  2021cites this paper
• Methylsulfonylmethane sensitizes endometrial cancer cells to doxorubicin

  2020cites this paper
• Peptide Hormone Regulation of DNA Damage Responses.

  2020cites this paper
• CMAR_A_221274 8905..8910

  2019cites this paper
• Downregulation Of LncRNA PMS2L2 In Endometrial Adenocarcinoma Upon Carboplatin Treatment

  2019cites this paper
• Cisplatin-Induced Ototoxicity: Updates on Molecular Targets.

  2019cites this paper
• The effects of growth hormone on therapy resistance in cancer

  2019cites this paper
• Systemic Complications of Acromegaly and the Impact of the Current Treatment Landscape: An Update.

  2018cites this paper
• Tumour-Derived Human Growth Hormone As a Therapeutic Target in Oncology.

  2017cites this paper
• Induction of Cisplatin Resistance by Hormones in Breast Cancer

  2017cites this paper
• Protein Kinase C Delta restrains growth in ACTH-secreting pituitary adenoma cells.

  2016cites this paper